IngredientsPunicalagins are the principal ellagitannins of the pomegranate plant (Punica granatum L., family Lythraceae). Punicalagin (PUN) is an ellagitannin, a type of water-soluble, hydrolyzable tannin with high molecular weight, present in α and β isomeric forms in plants of the order Myrtales. The compound is registered under CAS number 65995-63-3. The chemical structure of punicalagin consists of gallagic acid and ellagic acid connected through a glucose molecule, and it has two (α and β) isomeric forms that can be found in the pomegranate.
Punicalagin is the known largest molecular weight polyphenol. Among the pomegranate ellagitannins, punicalagin, which has a molecular weight of greater than 1,000, is reported to be responsible for more than half the potent antioxidant activity of the juice. Hydrolyzable tannins are a type of tannin in which several gallic acid units or dimers are linked to glucose, forming highly hydroxylated compounds of molecular weight 1,000 or greater. Pomegranate (Punica granatum) fruit is a botanical source of hydrolyzable tannins such as punicalagin and punicalin.
Punicalagin is present in α and β isomeric forms in plants of the genera Myrtales, including Terminalia myriocarpa, Terminalia catappa, and Punica granatum. Its main source is the aril, husk, fruit, juice, and peel of pomegranate (Punica granatum). It has also been identified in α and β forms in numerous species of the Terminalia genus, including T. arjuna (bark), T. chebula (leaves, fruit), T. catappa (bark), and several others, as well as in Lafoensia pacari leaves.
Punicalagin is the largest polyphenol among the ellagitannins, present mostly in the pomegranate peel. Pomegranate juice is also considered a great source of hydrolyzable tannins, in particular ellagitannins, as these compounds are the main class of identified polyphenolics. A broad array of ellagitannin structures has been found in pomegranate juice, with punicalagins and punicalins being the predominant ones. Ellagitannins are extensively found in pomegranate husk and membranes and are usually extracted into juice during processing.
Significant differences in ellagitannin levels exist among various pomegranate germplasms, with wild, sour-tasting varieties typically exhibiting higher total polyphenol and punicalagin content. Tissue-specific analysis further reveals that punicalagin accumulates most prominently in the placental tissue of pomegranates. Additionally, developmental studies confirm that the content of total polyphenols, total flavonoids, total flavanols, and punicalagin in various pomegranate organs declines throughout development, with a corresponding decrease in antioxidant activity.
Punicalagins are commercially available in several standardized forms derived from pomegranate:
Since ancient times (4000–3000 BCE), pomegranate has been familiar to people across different civilizations. The history of cultivation and consumption of pomegranate can be dated back to 3000 BC. It is documented in traditional Chinese medicine and other traditional medicines, including Indian, Cuban, and Greek traditional medicine.
Pomegranate has also been extensively used as a folk medicine in many cultures, documented at least as early as circa 1550 BCE in the Egyptian Ebers Papyrus. It has been used by Egyptians as a remedy for multiple infections and in Unani medicine as a treatment against diabetes.
Traditional medical systems across Eurasia have employed Punica granatum for centuries in a wide range of therapeutic applications. In Persian–Islamic medicine, the plant was used as a tonic to strengthen gastric function and to treat gastrointestinal disorders, respiratory diseases, skin wounds, reproductive health problems, and metabolic disturbances.
In Ayurveda, the ancient Indian medicinal system, pomegranate is recommended for the treatment of diarrhea and ulcers and as an antiparasitic. In Chinese folk medicine, pomegranate is used for its antioxidant, anti-inflammatory, neuroprotective, antibacterial, antiviral, antidiabetic, and anticancer properties, and to improve memory.
Chinese and Mexican populations have historically used pomegranate exocarp to cure gastrointestinal conditions like diarrhea, dysentery, and stomachaches. The antidiarrheal activities of punicalagin, corilagin, and ellagic acid (found in ethyl acetate fraction) alone or in combination have been confirmed.
In India, fruit juice is traditionally used to treat dysentery by mixing it with warm water twice daily, and is given to anemic people as a tonic. Ash produced by burning seeds has a styptic quality. Fruits are consumed in their natural form to treat jaundice and strengthen the heart. Bark powder is used as an astringent.
It is important to note that punicalagin as an isolated compound was not itself identified or named in any of these traditional systems; the traditional use refers to pomegranate preparations broadly (peel decoctions, juice, bark powder, seed ash), which we now know to be rich in punicalagins. Though pomegranate has long-standing traditional and ethnomedical applications, Punica granatum has only garnered rigorous scientific attention during the past two decades.
Ellagitannins are a family of bioactive polyphenols that exist in fruits such as pomegranates, strawberries, almonds, raspberries, and walnuts. Within pomegranate, punicalagins co-occur with a range of other bioactives, including punicalin, ellagic acid, gallic acid, and anthocyanins. Anthocyanins are mostly present in the flowers, peels, leaves, and arils. The color of the pomegranate mostly depends on the concentrations of anthocyanins present. Together with hydrolyzable tannins (polyphenols), they produce the overall antioxidant properties.
Punicalagin exhibits a potent antioxidant effect. Its antioxidant activity stems from its large polyhydroxylated structure, which enables efficient free radical scavenging. At the molecular level, punicalagin downregulates inflammation-related proteins cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), and enhances nuclear factor erythroid-2-related factor-2 (Nrf2) and heme oxygenase-1 (HO-1) expression. Activation of the Nrf2/HO-1 axis is recognized as one of the primary pathways through which punicalagin exerts cytoprotection against oxidative stress.
Punicalagin is considered to be the major active component of pomegranate extracts. Research has focused on recent studies into the therapeutic effects of punicalagin on inflammation-associated chronic diseases and the regulatory roles in NF-κB, MAPK, IL-6/JAK/STAT3, and PI3K/Akt/mTOR signaling pathways.
In lipopolysaccharide (LPS)-induced RAW264.7 macrophages, punicalagin significantly attenuated, in a concentration-dependent manner, LPS-induced release of nitric oxide (NO) and decreased pro-inflammatory cytokines TNF-α and IL-6. Punicalagin inhibited NF-κB and MAPK activation in these cells.
Punicalagin suppressed inflammatory-related pathways, including mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) signaling pathways in TNF-α/IFN-γ–stimulated HaCaT cells. At concentrations ≥10 μM and ≥3 μM, it significantly increased sirtuin 1 (SIRT1) expression and inhibited signal transducer and activator of transcription 3 (STAT3) phosphorylation, respectively.
In the context of macrophage biology, punicalagin treatment attenuated pyroptosis by downregulating the expression of NLRP3 and caspase-1, thereby preventing inflammatory cell death resulting from the release of IL-1β and IL-18. Mechanistically, punicalagin inhibited the activation of receptor activators of the NF-κB signaling pathway, which contributes to M1 macrophage polarization and pyroptosis.
Punicalagin has also been shown to downregulate the mRNA and soluble protein expression of IL-2 from anti-CD3/anti-CD28 stimulated murine splenic CD4+ T cells, and to inhibit the activation of the nuclear factor of activated T cells.
In rheumatoid arthritis models, punicalagin suppressed TNF-α–induced phosphorylation of IKKβ and IκBα, and the intracellular translocation of p65, suggesting that punicalagin regulated NF-κB pathway activation via interfering in early IKK signaling pathway. Treatments with punicalagin alleviated synovial inflammation and bone destruction in vivo without hepatocyte or glomerular injury.
A chemoinformatic analysis predicted, and in vitro inhibition assays confirmed, that topoisomerases I and II are potential biological targets of punicalagin, providing a novel mechanistic basis for its antifungal activity.
The bioavailability profile of punicalagins is a defining pharmacokinetic feature. Ellagitannins like punicalagin cannot be absorbed directly in humans. First, it converts to ellagic acid, which is further converted to the bioavailable urolithin A derivative by human colonic microflora.
The poor oral bioavailability of punicalagin is driven primarily by extensive intestinal first-pass metabolism rather than hepatic clearance, and its feces-dominant elimination is compatible with widespread hydrolysis and microbiota-mediated conversion within the gut.
Punicalagin is readily hydrolyzed in the small intestine to yield ellagic acid and is further converted by the gut microbiota into urolithins and related dibenzopyranone derivatives. When unabsorbed ellagitannins and free ellagic acid reach the colon, they are metabolized by gut microbiota to yield a family of microbial metabolites called urolithins.
Owing to their lipophilic nature, urolithins readily cross the intestinal epithelium and enter systemic circulation; however, their bioavailability is highly dependent on individual gut microbiota composition. This variability is largely explained by distinct urolithin metabotypes (UMs). Current research classifies individuals into three UM subgroups: UM-A, capable of producing urolithin A and its conjugates; UM-B, which yields urolithin A, iso-urolithin A, and urolithin B; and UM-0, in whom no urolithin metabolites are detected.
A small amount of punicalagin itself was detected in plasma and urine in rats, particularly after a long period of intake, but this has not been confirmed in further studies in humans in which dietary-relevant amounts of pomegranate ellagitannins were supplied. This indicates that for practical purposes, the circulating bioactive species in humans following punicalagin ingestion are predominantly the downstream metabolites: ellagic acid and urolithins.
The antioxidant capacity of punicalagins is among its most extensively documented properties. Among the pomegranate ellagitannins, punicalagin is reported to be responsible for more than half the potent antioxidant activity of the juice. The bulk of this evidence derives from in vitro assays (DPPH, ORAC, FRAP) and cell-based models, with limited human data specifically attributing antioxidant effects to isolated punicalagin rather than whole pomegranate juice or extract. Evidence strength for the antioxidant property is therefore considered strong at the in vitro level, preliminary at the human clinical level.
A 2026 evidence-based review highlights the cardioprotective potential of punicalagin as a major polyphenolic ellagitannin from Punica granatum. Preclinical studies demonstrate that punicalagin reduces oxidative stress via Nrf2/HO-1 and AMPK pathways, suppresses inflammatory cytokines (TNF-α, IL-1β, IL-6) through NF-κB and MAPK inhibition, improves endothelial function by upregulating eNOS, and modulates lipid metabolism through ApoB100 binding and cholesterol efflux. Clinical trials further support these effects, showing improvements in lipid profile, blood pressure, and carotid intima-media thickness.
At the cellular level, a significant increase in cholesterol efflux was reported for IFN-γ–induced THP-1 foam cells treated with 10 μM of punicalagin compared to vehicle control, with percentages of cellular cholesterol efflux of 54.2% versus 40% in controls in the presence of IFN-γ.
Human clinical evidence: Two notable randomized controlled trials investigated a combination supplement containing hydroxytyrosol (HT) and punicalagin (PC):
Evidence strength: Preclinical (in vitro and animal) evidence for cardiovascular protection is robust. Human clinical evidence is preliminary but directionally consistent, limited primarily by the fact that the clinical trials used combination products containing both hydroxytyrosol and punicalagin, making it impossible to attribute effects to punicalagin alone. Larger, punicalagin-specific trials are lacking.
Inflammation is a complex biological defense system associated with a series of chronic diseases such as cancer, arthritis, diabetes, cardiovascular and neurodegenerative diseases. Punicalagin's anti-inflammatory effects have been extensively studied in preclinical models.
The aggressive phenotype of fibroblast-like synoviocytes (FLSs) is essential in the synovitis and bone destruction of rheumatoid arthritis (RA). Punicalagin is a natural polyphenol with antioxidant, anti-inflammatory, and anti-tumor properties, suggesting it may be a potent agent for RA therapy. In one study, FLSs were isolated from synovial tissue of RA patients, and findings suggested that punicalagin was a potential treatment for RA.
Based on the overall body of preclinical research, punicalagin may be a promising therapeutic compound in preventing and treating inflammation-associated chronic diseases, although further clinical studies are required.
Evidence strength: The anti-inflammatory evidence is strong in cell-based and animal models, with well-characterized molecular mechanisms. Dedicated human clinical trials for inflammatory conditions remain absent in the available literature.
Punicalagin and its metabolites have been shown to inhibit angiogenesis, proliferation, and induce apoptosis in osteosarcoma cancer cells, prostate cancer, colon cancer, and cervical cancer cell lines. Punicalagin also suppresses various signaling pathways, including NF-κB, MAPK, Bcl-XL, and LKB1-AMPK-p27.
Punicalagin's anticancer properties are achieved by preventing autophagy, lowering apoptosis, stifling proliferation, and preventing cell viability, migration, and invasion.
Punicalagins are reported to have various anticancer properties against several cancer cell lines such as colon cancer, ovarian cancer, prostate cancer, and lung cancer cells by suppressing proliferation and inducing S-phase cell cycle arrest and apoptosis.
Punicalagin, as a dietary phytochemical, altered various cell signal transduction pathways associated with cell apoptosis and proliferation. Studies have examined the efficiency of punicalagin on cell viability and the molecular mechanisms of punicalagin-stimulated apoptosis by exploring the expression of Bcl-2 family proteins, caspases, and cell cycle regulatory proteins p53 and NF-κB signaling in human cervical cancer cells.
Pomegranate juice consumption has shown promising outcomes in clinical trials against various diseases, including diabetes, prostate cancer, and cardiovascular disorders, and these effects could be attributed to the punicalagin content of the juice.
Evidence strength: Anticancer evidence is limited to in vitro and animal studies for punicalagin specifically. While whole pomegranate products have been evaluated in some prostate cancer clinical trials, no phase II or III human clinical trials isolating punicalagin as the test intervention have been identified. The preclinical evidence is mechanistically interesting but insufficient to support clinical claims.
Pomegranate peel extract has been increasingly investigated for its antibacterial activity, with numerous studies demonstrating high efficacy, particularly against Gram-positive pathogens. The literature identifies punicalagin as one of the key compounds responsible for the antibacterial activity.
Pomegranate extracts have shown antifungal activity, and specific studies have investigated the inhibition ability of a selection of pomegranate phenolic compounds (including punicalagin, punicalin, ellagic acid, and gallic acid) on both plant and human fungal pathogens.
In a clinical application context, in a randomized controlled clinical trial, 62 patients with ulcerative colitis were treated with an aqueous extract of pomegranate peel (6 g of dry peel per day), and this resulted in a reduction of antidiarrheal medication need after 4 weeks.
Evidence strength: Antimicrobial evidence is primarily in vitro. The ulcerative colitis RCT used a whole pomegranate peel extract (not isolated punicalagin), limiting specificity. Clinical evidence for punicalagin's antimicrobial effects in humans is preliminary.
Punicalagin suppresses various signaling pathways, suggesting that it could have potential for therapeutics of various immune diseases, including brain damage and Alzheimer's disease. Punicalagin's neuroprotective properties have been reviewed alongside its antioxidant, anti-inflammatory, anticancer, cardioprotective, and antibacterial properties. The review analyzes punicalagin's mode of action and therapeutic possibilities for neuroprotection.
Punicalagin is defined as a unique ellagitannin known for its antioxidant, anti-inflammatory, antimicrobial, and antitumor properties, as well as its ability to alleviate obesity and oxidative stress through the activation of the Nrf2 signaling pathway.
Evidence strength: Neuroprotective evidence is at an early, primarily in vitro and preclinical stage. Human clinical data specifically investigating punicalagin's effects on cognitive or neurological outcomes are not available in the current literature. This remains an area of active investigation.
In a high-fat diet and streptozotocin-induced diabetic liver injury mouse model, the protective effect of punicalagin was observed. Fasting blood glucose, fasting serum insulin, and homeostasis model assessment for insulin resistance (HOMA-IR) in diabetic liver injury mice were significantly decreased after punicalagin intervention. Simultaneously, levels of alanine aminotransferase, aspartate aminotransferase, total cholesterol, triglyceride, LDL-C, free fatty acids, and malondialdehyde in the serum and liver were significantly decreased, with reductions in fat lesions and inflammatory cells.
Punicalagin's pharmacological effects include antioxidant, anticancer, antibacterial, neuroprotective, anti-inflammatory, antidiabetic, and antihyperlipidemic properties.
Evidence strength: Antidiabetic and antihyperlipidemic evidence for punicalagin is preclinical (animal models). The clinical data for whole pomegranate preparations suggest metabolic benefits, but punicalagin-specific human metabolic trials have not been identified.
In Persian–Islamic medicine, pomegranate was used as a tonic to strengthen gastric function and to treat gastrointestinal disorders. Similar applications are reported in Chinese and Mexican traditions, where the pomegranate exocarp has been used in the treatment of diarrhea and dysentery, which is associated with the presence of bioactive compounds such as punicalagin.
In a randomized controlled clinical trial, 62 patients with ulcerative colitis were treated with an aqueous extract of pomegranate peel (6 g of dry peel per day) and showed a reduction of antidiarrheal medication need after 4 weeks.
Evidence strength: GI evidence includes one RCT using pomegranate peel extract, making it the most clinically substantiated traditional use for punicalagin-containing preparations. However, as with all the clinical work to date, the intervention was a whole extract, not isolated punicalagin.
Based on the available preclinical and clinical literature, punicalagins have been associated with the following body systems and health areas:
Dosages reported in the scientific literature vary considerably depending on the study design, formulation, and target population. The following are dosages as stated in primary sources:
No established human therapeutic dose for isolated punicalagin has been defined in clinical guidelines or pharmacopeial monographs. All dosing information currently derives from preclinical studies or trials using multi-component pomegranate preparations.
In a 37-day repeated-dose study in rats given a 6% punicalagin-containing diet, feedstuff intake, food utility index, and growth rate were lower during the first 15 days without significant adverse effects. No significant differences were found in any blood parameter analyzed, including antioxidant enzymes. Histopathological analysis of liver and kidney corroborated the absence of toxicity.
In separate experiments, groups of Wistar rats and Swiss albino mice received a single dose of pomegranate fruit extract standardized to contain 70% polyphenols (including 30% punicalagins) at 0, 50, 500, or 5,000 mg/kg body weight via gavage. The oral LD50 was determined to be greater than 5,000 mg/kg body weight for both species. No adverse effects were observed during the 14-day observation period, and no gross pathological abnormalities were observed during necropsy.
The intraperitoneal LD50 in rats and mice was determined to be 217 and 187 mg/kg body weight, respectively. The "no-observed-adverse-effect level" (NOAEL) was determined to be 600 mg/kg body weight/day.
However, contrasting findings have also been reported: while acute toxicity studies report no adverse effects in mice at doses ≤2,000 mg/kg, chronic exposure to high-dose punicalagin (≥12.5 mg/kg) has been reported to induce hepatotoxicity in rats, marked by elevated liver enzymes and lipid peroxidation. Some concerns regarding long-term toxicity have been raised and should incite further exploration of its safety.
The evidence of clinical effectiveness from pomegranate-specific cancer studies was limited by poor study quality. Although there is no concern over safety at the doses used in those clinical studies, pomegranate preparations may be harmful by inducing synthetic drug metabolism through activation of liver enzymes.
In the hydroxytyrosol and punicalagin crossover trial, the supplement exerted its effects without adverse effects being reported.
CYP450 enzyme interactions are a recognized concern. Many patients may consume pomegranate juice with or without their doctor's knowledge, which may raise significant medication errors or benefits because of food-drug interactions that modulate a drug's pharmacokinetics or pharmacodynamics.
Pomegranate juice contains large amounts of polyphenols, mainly tannins such as ellagitannin, punicalagin, and punicalin. These constituents have been shown to inhibit cytochrome P450 (CYP450) activities such as CYP3A4 and CYP2C9.
However, in vitro findings do not appear to translate linearly to humans. Clinical research shows that neither pomegranate juice nor pomegranate extract has a significant effect on CYP2C9 activity in humans. In an animal model, pomegranate juice inhibits CYP3A4 metabolism of carbamazepine; however, in human volunteers, drinking 240 mL of pomegranate juice or taking 200 mL daily for 2 weeks does not significantly affect levels of the CYP3A4 substrate midazolam. Another study in healthy volunteers shows that consuming pomegranate juice 300 mL three times daily for three days also does not significantly affect levels of simvastatin, a CYP3A4 substrate. This suggests that pomegranate is unlikely to significantly affect levels of CYP3A4 substrates in humans.
Warfarin interaction: Observational studies reported that pomegranate juice prolonged the pharmacodynamics of warfarin. A case report has described such an interaction in a patient receiving warfarin for recurrent deep vein thrombosis who was consuming pomegranate juice several times per week. This potential pharmacodynamic interaction warrants caution in patients on anticoagulant therapy, even though mechanistic certainty is not established in controlled human studies.
The water-soluble ellagitannin punicalagin has been reported to be toxic to cattle. This is a species-specific finding and does not directly translate to human safety assessments, but underscores the importance of species-appropriate dosing in interpreting toxicological data.
Pomegranate products have been analyzed for their content of anthocyanins, punicalagin, and ellagic acid in order to compare them with benchmark doses from published data. If the amount of co-active constituents is not declared, patients risk not benefiting from the putative pomegranate effects. This highlights a practical concern for consumers and clinicians evaluating pomegranate-derived supplements.
Punicalagins represent one of the most chemically distinctive and pharmacologically active polyphenol classes in the human diet. The antioxidant, anti-inflammatory, anticancer, and cardioprotective properties of punicalagin have been extensively investigated. Recent studies have shown that punicalagin has excellent bioactive as well as therapeutic potential, and it has been suggested as a safe alternative for chemoprevention. As a natural substance, punicalagin shows potential for improving health in several ways; however, its therapeutic potential and methods of action need further investigation.
The critical limitation across the research base is the relative scarcity of human clinical trials evaluating isolated punicalagin at defined doses. Most clinical evidence derives from studies using whole pomegranate juice, pomegranate peel extract, or combination formulations, making it difficult to attribute effects exclusively to punicalagins. Additionally, the high interindividual variability in gut microbiota composition—which determines whether and how efficiently punicalagins are converted to bioavailable urolithins—means that the biological effects of punicalagin ingestion are likely to vary substantially among individuals. Further clinical studies are required to establish dose-response relationships, optimal delivery forms, and efficacy for specific health outcomes in human populations.
Health conditions that Punicalagins may help support.
Punicalagins are the principal polyphenols of pomegranate with potent arterial antioxidant activity. They upregulate eNOS, inhibit LDL oxidation, and reduce endothelial adhesion molecule expression. A clinical trial combining punicalagins (195 mg/day) with hydroxytyrosol showed improved arterial function after 8 weeks. Pomegranate punicalagins contributed to the 30% reduction in carotid IMT in a 3-year clinical study.
Punicalagins are the principal polyphenols of pomegranate and hydrolyze to ellagic acid, providing photoprotection and tyrosinase inhibition relevant to hyperpigmentation. They are identified in reviews of herbal treatments for melasma as examples of UV-protective and antimelanogenic agents.
Punicalagins are the primary polyphenolic ellagitannins in pomegranate, responsible for its potent antioxidant and anti-inflammatory effects documented in CKD and dialysis patients. They hydrolyze to ellagic acid and are metabolized to urolithins with nephroprotective properties. Clinical pomegranate studies demonstrating reduced inflammation and oxidative stress in hemodialysis patients are largely attributable to punicalagins as the dominant bioactive.
Punicalagins are the primary polyphenolic compounds in pomegranate peel responsible for its documented antiparasitic activity against Giardia lamblia and Haemonchus contortus in PMC-published in vitro and animal studies.
Body systems that Punicalagins may help support.
Go back